ACE and atrial fibrillation: There has therefore been considerable interest in whether drugs targetted to the RAAS, such as angiotensin‐converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB), reduce the incidence of AF or its recurrence in at‐risk patients (Healey et al. 2005a; Schneider et al. 2010; Galzerano et al. 2012).